TD Cowen lowered the firm’s price target on Biodesix (BDSX) to $2 from $3 and keeps a Buy rating on the shares. The firm updated its model as sales force issues were a drag on 1Q results and the guide down.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX: